2024年12月19日上午9时30分,科济药业-B(02171)股价在港股盘中突然出现大涨超过6%的异动。据悉,造成这一走势的原因很可能与该公司在研发创新CAR-T细胞疗法方面取得进展有关。
作为一家专注于创新免疫细胞疗法的公司,科济药业-B的核心产品是升级版靶向B细胞成熟抗原(BCMA)的CAR-T疗法CT053,用于治疗血液肿瘤及实体瘤。公司可能在相关临床试验或监管审批等环节获得利好消息,提振了市场对公司长期发展前景的信心。
不过,由于尚无确切的消息来源可供佐证,上述推测仍需进一步的官方披露或报道予以证实。科济药业-B此次大涨究竟是基于什么实质性进展,市场拭目以待公司的进一步说明。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.